About SORAMEDAI

A physician-only review layer for the regulated era of medical AI.

The FDA has cleared more than a thousand AI-enabled medical devices. The EU AI Act has put clinical AI in its highest-risk tier. Frontier models answer medication and triage questions millions of times a day. SORAMEDAI is the specialist layer that evaluates those outputs the way a regulator, a hospital safety committee or a malpractice attorney eventually will — with practising physicians, on the record.

Better Data. Better AI. Better Patient Outcomes.

01The market context

Healthcare AI is now a regulated product category — and the data layer hasn't caught up.

The FDA has authorised more than 1,000 AI / ML-enabled medical devices, the EU AI Act has classified clinical AI as high-risk, and frontier model providers are racing to ship medical assistants. Yet most of the data those systems learn from is still labelled by generalist crowd workers grading fluency, not clinical safety. SORAMEDAI exists to be the physician-only layer that fits between a model and a regulator.

02Where we sit

Not a crowd platform. Not an in-house clinical team. A specialist network in between.

Generalist labeling vendors are excellent at volume but were never built to adjudicate a warfarin interaction. In-house medical review is rigorous but slow and expensive. There is a clear and growing appetite for expert-led review — SORAMEDAI's contribution is a tightly held, physician-only network with triple-blind consensus on every task and an audit trail built for regulators from day one.

03What we believe

Clinical safety is a judgement, not a vibe check.

A confident, fluent answer is not a safe answer. Whether an AI medical output is appropriate depends on drug interactions, comorbidities, red-flag symptoms and the local standard of care — judgements that require real medical training. We treat every label as a clinical decision, document the reasoning, and surface disagreement instead of hiding it behind a majority vote.

04How we work

Triple-blind consensus. Senior adjudication. Full audit trail.

Every task is reviewed independently by three USMLE-qualified physicians who never see one another's answers. A senior MD adjudicates disagreements. Inter-annotator agreement, failure-mode analysis and written clinical reasoning ship with every delivery — evidence safety teams can submit to the FDA, an EU AI Act conformity assessment or an enterprise procurement review.

05Where the network comes from

Thousands of US-trained physicians the residency system never absorbed.

Each year, thousands of international medical graduates — many in Pakistan — pass USMLE Steps 1, 2 and 3 but do not match into US residency. They hold the same exams, the same pharmacology, the same standard of care as their matched peers, and almost nowhere to apply it. SORAMEDAI gives that under-used clinical talent a meaningful surface, and gives AI teams access to a calibre of reviewer that is structurally hard to source at scale anywhere else.

06What we will not do

We don't label what we aren't qualified to label.

We are not a general-purpose data vendor. We don't take on bounding boxes for autonomous vehicles, content moderation, or non-clinical NLP. Every project we accept has a clinical safety question at its core — medication, diagnosis, triage, documentation, red-team — because that is the only place a physician-only network is the right tool.

The landscape

Where SORAMEDAI sits, in plain terms.

The annotation market is crowded. The clinical end of it isn't. Here is how we read the room.

  • 01

    Generalist crowd platforms

    Crowd labeling platforms

    Them

    Optimised for throughput across every domain. Reviewers are smart, fast and rarely clinically trained.

    SORAMEDAI

    Every reviewer holds an MBBS and has passed USMLE Steps 1, 2 and 3. No task is graded by a non-physician.

  • 02

    Healthcare-adjacent vendors

    ​

    Them

    Mixed networks of radiologists, coders, scribes and clinicians, often single-reviewer with QA sampling.

    SORAMEDAI

    Triple-blind consensus on every task with senior MD adjudication and inter-annotator agreement reported by default.

  • 03

    In-house clinical review

    Your own MDs

    Them

    Highest-trust but slow to spin up, expensive per hour, and difficult to scale past a handful of reviewers.

    SORAMEDAI

    A managed network you can hand twenty hours to this week and two thousand hours to next quarter, without hiring.

​

The principles we run on

Physicians or nothing.

If a task can be answered by a non-clinician, it is not a task for SORAMEDAI. We would rather decline work than dilute the network.

Disagreement is data.

When three doctors disagree on an AI output, that is a signal — not noise. We report it, we don't average it away.

Evidence by default.

Inter-annotator agreement, failure modes and written reasoning ship with every delivery. Built for the auditor, not the dashboard.

Work with us

Send us AI medical outputs you are least sure about. We'll return the consensus, the disagreements, and the clinical reasoning behind both — with evidence your safety team can actually file. Start the pilot →